Renal Cell Carcinoma

Why trials studying Renal Cell Carcinoma stopped, in this sample of ClinicalTrials.gov.

23 stopped trials with a clear reason; 83% ended for non-scientific reasons.

Trials

• Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001)
  NCT05721222 · TERMINATED · funding business
  “Genmab has decided to discontinue the clinical development of GEN1160 due to slow enrolment”
• NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
  NCT05714553 · TERMINATED · funding business
  “The NuTide:303 study was terminated at NuCana's discretion following refinement of the NUC-3373 development strategy.”
• A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona
  NCT05418387 · WITHDRAWN · logistics pi
  “The study will be withdrawn as the Principal Investigator, Ken Batai, left the institution prior to study activation.”
• Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors
  NCT04628780 · TERMINATED · funding business
  “Pfizer has made an internal business decision to not continue further development of PF-07209960. This decision was not based on safety or regulatory considerations”
• A Study of PY314 in Subjects With Advanced Solid Tumors
  NCT04691375 · TERMINATED · funding business
  “Sponsor business decision.”
• Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
  NCT04234113 · TERMINATED · futility
  “Due to lack of efficacy shown at the time of the interim analysis.”
• Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
  NCT04106167 · TERMINATED · funding business
  “This study was terminated by the Sponsor.”
• A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
  NCT03829501 · TERMINATED · funding business
  “Early discontinuation based on strategic sponsor decision not driven by any safety concerns.”
• Functional Microscale Organotypic Assays to Predict Patient Response to Anti-Angiogenesis Therapies
  NCT03387514 · TERMINATED · slow accrual
  “Termination of funding due to low subject enrollment due to change in standard of care systemic therapy which limited available patients treated with anti-angiogenesis or combined immune and anti-angiogenesis therapy for enrollment.”
• APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC
  NCT03655613 · TERMINATED · logistics pi
  “Study terminated due to administrative reasons.”
• Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma
  NCT03393936 · TERMINATED · funding business
  “Adjustment of study strategy”
• REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies
  NCT03435640 · TERMINATED · funding business
  “Based on the overall results from the Phase 1 part of the study the sponsor decided to end the study. The decision was not due to safety reasons.”
• Healthcare Cost and Resource Utilization Related to Metastatic Renal Cell Carcinoma Treatment With Intravenous and Oral Agents
  NCT02928263 · WITHDRAWN · funding business
  “Business objectives have changed”
• Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus (ORCHIDEE)
  NCT02338570 · TERMINATED · slow accrual
  “Stopped on November 16th 2016, because of recruitment failure.”
• Investigating a Novel Modifiable Factor Affecting Renal Function After Partial Nephrectomy: Cortical Renorrhaphy
  NCT02131376 · TERMINATED · futility
  “slow accrual, interim analysis showed no statistical significance”
• A Pilot/Phase II Study of Gamma Knife Radiosurgery for Brain Metastases Using 3Tesla MRI and Rational Dose Selection
  NCT02005614 · TERMINATED · slow accrual
  “Unable to recruit patients.”
• Contrast-Enhanced Ultrasound in Predicting Treatment Response in Patients With Kidney Cancer Undergoing Cryosurgery
  NCT02671552 · WITHDRAWN · regulatory
  “Terminated by the IRB”
• Novel Controlled Hypo-Perfusion Technique in Partial Nephrectomy
  NCT01720693 · TERMINATED · slow accrual
  “Low accrual”
• Brivanib Metastatic Renal Cell Carcinoma
  NCT01253668 · TERMINATED · funding business
  “In November 2012, this study was permanently closed to new accrual at the request of the drug manufacturer (BMS), who decided not to pursue additional research activity in this patient population.”
• A Rollover Protocol for Subjects Previously Treated With AGS-003
  NCT01482949 · TERMINATED · futility
  “Lack of efficacy”
• Genetic Susceptibility to Kidney Cancer
  NCT00854022 · TERMINATED · funding business
  “Funding ended”
• [18]F-FAZA PET Imaging Study in Patients With Cancer of the Head & Neck, Lung, Renal Cell, Brain, Lymphoma and Neuroendocrine Tumours
  NCT00323076 · TERMINATED · funding business
  “Retirement of former Qualified Investigator and lack of resources to complete study.”
• Study of XL999 in Patients With Metastatic Renal Cell Carcinoma
  NCT00277316 · TERMINATED · safety
  “Development of XL999 was stopped due to cardiac toxicities in the subjects”

Reasons are labeled automatically and are unverified. See the methodology. This is research information, not medical advice. Search the full database.